Lovick Edward Cannon

AdipoGenix, Inc. develops molecular pharmaceutical products. It offers small molecule pharmaceuticals to treat obesity and its co-morbidities. The firm’s technology includes AdipoBASE, AdipoSCREEN, AdipoPATH and AdipoTARGET. The company was founded by Gerri Waloga, Barbara E. Corkey, Stephen R. Farmer, James A. Hamilton, James L. Kirkland, H. Jeff Leighton and Paul F. Pilch in 1997 and is headquartered in Boston, MA.

Elixir Pharmaceuticals, Inc. operates as a holding company with interest in manufacturing and developing biopharmaceutical products for the treatment of metabolic diseases such as diabetes and obesity. The company was founded by Leonard Guarente, Cynthia J. Kenyon, Cindy Bayley, Louis Kunkel, Annibale Puca, and Thomas Perls in 1999 and is headquartered in Cambridge, MA.

Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA.

Part of Takeda Pharmaceutical Co., Ltd., Protein Engineering Corp is a company that screens proteins and peptides used in drug discovery. The company is based in Cambridge, MA. Protein Engineering was acquired by Dyax Corp., part of Takeda Pharmaceutical Co., Ltd. from January 25, 2016 on November 15, 1995.

SmartCells, Inc. develops glucose-regulated smart insulin products for the treatment of diabetes. The company was founded by Todd C. Zion and James M. Herriman in 2003 and is headquartered in Beverly, MA.

Part of Econet, Inc., Unigen Pharmaceuticals, Inc. operates a research and development company that manufactures and supplies pharmaceutical and biologically active ingredients. The company is based in Lacey, WA. The CEO of the company is Lovick Edward Cannon.

NovAb, Inc. provides healthcare services. The company was incorporated in 2013 and is headquartered in Tucker, GA.

Akston Biosciences Corp. engages in the development of biologic therapeutics for use in autoimmune Type 1 diabetes prevention. It offers novel vaccine, disrupt insulin autoimmunity to prevent type 1 diabetes, and controlled hypoglycemia to enhance anti-tumor cancer therapy. The company was founded by Todd C. Zion in 2011 and is headquartered in Beverly, MA.